Table 3.
Comparison of Patient Clinical Characteristics between the CKD and Non-CKD Groups.
| CKD (n=54) | non-CKD (n=72) | p value | ||||
|---|---|---|---|---|---|---|
| Age (years) | 70.0 [60.0, 75.0] | 61.0 [50.0, 71.0] | <0.001 | |||
| Female | 17 (31) | 28 (39) | 0.39 | |||
| BMI (kg/m2) | 25.1 [22.9, 29.5] | 25.3 [22.5, 28.5] | 0.919 | |||
| History of ACS | 17 (31) | 14 (19) | 0.121 | |||
| History of AMI | 10 (19) | 13 (18) | 0.947 | |||
| History of UAP | 7 (13) | 1 (1) | 0.008 | |||
| History of SIHD | 9 (17) | 3 (4) | 0.018 | |||
| History of PCI | 24 (44) | 17 (24) | 0.014 | |||
| History of CABG | 1 (2) | 1 (1) | 0.837 | |||
| History of PAD | 7 (13) | 2 (3) | 0.028 | |||
| History of HF | 4 (7) | 3 (4) | 0.432 | |||
| Hypertension | 37 (69) | 34 (47) | 0.017 | |||
| Diabetes mellitus | 29 (54) | 41 (57) | 0.638 | |||
| Cerebral infarction | 8 (15) | 7 (10) | 0.382 | |||
| Malignancy | 7 (13) | 6 (8) | 0.398 | |||
| Current smoker | 15 (28) | 16 (22) | 0.474 | |||
| Medical therapy on admission | ||||||
| Statin | 34 (63) | 30 (42) | 0.018 | |||
| Ezetimibe | 14 (26) | 13 (18) | 0.287 | |||
| PCSK9I | 1 (2) | 0 (0) | 0.246 | |||
| N-3 fatty acid sequestrants | 6 (11) | 11 (15) | 0.643 |
Data are presented as the median [25%, 75%] or n (%). p<0.05 vs. non-CKD by Mann-Whitney U test.
CKD: chronic kidney disease, BMI: body mass index, ACS: acute coronary syndrome, AMI: acute myocardial infarction, UAP: unstable angina pectoris, SIHD: stable ischemic heart disease, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, PAD: peripheral artery disease, HF: heart failure, PCSK9I: proprotein convertase subtilisin/kexin type-9 inhibitor